Back to Browse Journals » Drug Design, Development and Therapy » Volume 11

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma

Authors Friend R, Bhutani M, Voorhees PM, Usmani SZ

Received 11 November 2016

Accepted for publication 10 January 2017

Published 20 March 2017 Volume 2017:11 Pages 893—900

DOI https://doi.org/10.2147/DDDT.S98053

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Frank Boeckler

Reed Friend, Manisha Bhutani, Peter M Voorhees, Saad Z Usmani

Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, UNC School of Medicine, Charlotte, NC, USA

Abstract:
Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations.

Keywords: multiple myeloma, relapsed, refractory, treatment, elotuzumab, SLAMF7, CS1

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]